Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV ...
These solid data provide proof of concept that topical antiretrovirals can serve as effective anti-HIV microbicides. Given the efficacy and pharmacology of tenofovir in HIV treatment, and the positive ...
Tenofovir decreases HSV-2 risk Oral tenofovir-based prophylaxis for HIV also reduced herpes simplex virus-2 transmission. Daily oral tenofovir-based preexposure prophylaxis (PrEP) for HIV also seemed ...
A group of researchers led by Xavier Saelens and Sven Eyckerman at the VIB-UGent Center for Medical Biotechnology discovered how a protein linked to the human immune system wards off HIV-1 and herpes ...
– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – “These data presented for ABI-5366 and ABI-1179 continue to support ...
First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine ...
Prevention—what doesn’t work? In a session entitled “Status of the U.S. HIV/AIDS Epidemic: Is It Changing and If Not, Why Not?” Harold Jaffe, MD, former head of the CDC, discussed a not-yet-published ...
Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...
A photomicrograph image of herpes virus antibodies detected using immunofluorescent staining technique, 1977. Image courtesy CDC/Dr. Craig Lyerla. (Photo by Smith Collection/Gado/Getty Images) A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results